XTalks
APRIL 11, 2024
After backing from the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) last month, Johnson and Johnson (J&J) and Bristol Myers Squibb (BMS) scored FDA approvals for the use of their B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies as earlier line treatment options for multiple myeloma.
Clinical Trial Podcast
DECEMBER 29, 2022
In this episode, I’m excited for you to learn about Heart Failure Clinical Trials for medical devices. Sonna and her team successfully completed enrollment in an FDA-approved feasibility trial and are now working towards the next phase of their medical product development lifecycle. To learn more, visit [link].
The Pharma Data
JANUARY 24, 2021
In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.
Expert insights. Personalized for you.
52 
Let's personalize your content